<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="jeo270180" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Orthop</journal-id><journal-id journal-id-type="iso-abbrev">J Exp Orthop</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2197-1153</journal-id><journal-id journal-id-type="publisher-id">JEO2</journal-id><journal-title-group><journal-title>Journal of Experimental Orthopaedics</journal-title></journal-title-group><issn pub-type="epub">2197-1153</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39949712</article-id><article-id pub-id-type="pmc">PMC11822265</article-id>
<article-id pub-id-type="doi">10.1002/jeo2.70180</article-id><article-id pub-id-type="publisher-id">JEO270180</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Which treatment strategy for irreparable rotator cuff tears is most cost&#x02010;effective? A Markov model&#x02010;based cost&#x02010;utility analysis comparing superior capsular reconstruction, lower trapezius tendon transfer, subacromial balloon spacer implantation and reverse shoulder arthroplasty</article-title></title-group><contrib-group><contrib id="jeo270180-cr-0001" contrib-type="author"><name><surname>Oeding</surname><given-names>Jacob F.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4562-4373</contrib-id><xref rid="jeo270180-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jeo270180-cr-0002" contrib-type="author"><name><surname>Kunze</surname><given-names>Kyle N.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0363-3482</contrib-id><xref rid="jeo270180-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jeo270180-cr-0003" contrib-type="author"><name><surname>Pareek</surname><given-names>Ayoosh</given-names></name><xref rid="jeo270180-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jeo270180-cr-0004" contrib-type="author" corresp="yes"><name><surname>Samuelsson</surname><given-names>Kristian</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5383-3370</contrib-id><xref rid="jeo270180-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>kristian.samuelsson@gu.se</email></address></contrib></contrib-group><aff id="jeo270180-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Orthopaedics, Institute of Clinical Sciences, The Sahlgrenska Academy</named-content>
<institution>University of Gothenburg</institution>
<city>Gothenburg</city>
<country country="SE">Sweden</country>
</aff><aff id="jeo270180-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Orthopaedic Surgery</named-content>
<institution>Hospital for Special Surgery</institution>
<city>New York</city>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold> Kristian Samuelsson, Department of Orthopaedics, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, M&#x000f6;lndal, SE&#x02010;431 80 M&#x000f6;lndal, Sweden.<break/>
Email: <email>kristian.samuelsson@gu.se</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2025</year></pub-date><volume>12</volume><issue seq="39">1</issue><issue-id pub-id-type="doi">10.1002/jeo2.v12.1</issue-id><elocation-id>e70180</elocation-id><history>
<date date-type="rev-recd"><day>22</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>20</day><month>10</month><year>2024</year></date>
<date date-type="accepted"><day>23</day><month>12</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 The Author(s). Journal of Experimental Orthopaedics published by John Wiley & Sons Ltd on behalf of European Society of Sports Traumatology, Knee Surgery and Arthroscopy.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Journal of Experimental Orthopaedics</italic> published by John Wiley &#x00026; Sons Ltd on behalf of European Society of Sports Traumatology, Knee Surgery and Arthroscopy.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JEO2-12-e70180.pdf"/><abstract><title>Abstract</title><sec id="jeo270180-sec-0010"><title>Purpose</title><p>Treatment options for irreparable rotator cuff tears (IRCTs) remain controversial and include superior capsular reconstruction (SCR), lower trapezius tendon transfer (LTTT), subacromial balloon spacer (SABS), and reverse shoulder arthroplasty (RSA). Despite reports of positive treatment responses with all approaches, the relative clinical benefit in the context of associated cost has not been well delineated. The purpose of this study was to determine the most cost&#x02010;effective treatment strategy among SCR, LTTT, SABS, and RSA for patients with massive IRCTs.</p></sec><sec id="jeo270180-sec-0020"><title>Methods</title><p>A Markov Chain Monte Carlo probabilistic model was developed to evaluate the outcomes and costs of 1000 simulated patients undergoing either SCR, LTTT, SABS, or RSA for massive IRCTs. Upfront costs, health utility values, and reoperation rates including revisions and conversion to RSA were derived from the published literature. Outcome measures included costs, quality&#x02010;adjusted life years (QALYs), and the incremental cost&#x02010;effectiveness ratio (ICER).</p></sec><sec id="jeo270180-sec-0030"><title>Results</title><p>Mean total costs of SCR, RSA, LTTT, and SABS were $30,540&#x02009;&#x000b1;&#x02009;5,770, $26,896&#x02009;&#x000b1;&#x02009;5,622, $25,819&#x02009;&#x000b1;&#x02009;4,325, and $16,412&#x02009;&#x000b1;&#x02009;2,583, respectively. On average, total QALYs from SCR, RSA, LTTT, and SABS were 6.17&#x02009;&#x000b1;&#x02009;0.53, 3.78&#x02009;&#x000b1;&#x02009;0.38, 5.33&#x02009;&#x000b1;&#x02009;0.49, and 5.59&#x02009;&#x000b1;&#x02009;0.48. Overall, SCR was determined the preferred, most cost&#x02010;effective strategy in 60% of patients included in the microsimulation model, with SABS the optimal strategy in 31% of cases and LTTT the optimal strategy in 9% of cases.</p></sec><sec id="jeo270180-sec-0040"><title>Conclusion</title><p>SCR was found to be the most cost&#x02010;effective treatment option for IRCTs based on the current microsimulation and probabilistic sensitivity analyses, although LTTT and SABS were also found to be cost&#x02010;effective in select patients. Given that this statistical model does not consider the unique experiences of individual patients, shared decision&#x02010;making remains an important component in determining the optimal treatment strategy for IRCTs.</p></sec><sec id="jeo270180-sec-0050"><title>Level of Evidence</title><p>Level III, economic decision model.</p></sec></abstract><kwd-group><kwd id="jeo270180-kwd-0001">cost&#x02010;effectiveness</kwd><kwd id="jeo270180-kwd-0002">irreparable rotator cuff tear</kwd><kwd id="jeo270180-kwd-0003">Markov model</kwd><kwd id="jeo270180-kwd-0004">reverse shoulder arthroplasty</kwd><kwd id="jeo270180-kwd-0005">superior capsular reconstruction</kwd></kwd-group><counts><fig-count count="5"/><table-count count="2"/><page-count count="11"/><word-count count="5253"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jeo270180-cit-0032">
<string-name>
<surname>Oeding</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Kunze</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>Pareek</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Samuelsson</surname>
<given-names>K</given-names>
</string-name>. <article-title>Which treatment strategy for irreparable rotator cuff tears is most cost&#x02010;effective? A Markov model&#x02010;based cost&#x02010;utility analysis comparing superior capsular reconstruction, lower trapezius tendon transfer, subacromial balloon spacer implantation and reverse shoulder arthroplasty</article-title>. <source>J Exp Orthop</source>. <year>2025</year>;<volume>12</volume>:<elocation-id>e70180</elocation-id>. <pub-id pub-id-type="doi">10.1002/jeo2.70180</pub-id>
<pub-id pub-id-type="pmid">39949712</pub-id>
</mixed-citation>
</p></notes></front><body><def-list list-content="abbreviations"><title>Abbreviations</title><def-item><term>ASES</term><def><p>American Shoulder and Elbow Surgeons</p></def></def-item><def-item><term>CMS</term><def><p>Constant&#x02010;Murley score</p></def></def-item><def-item><term>ICER</term><def><p>incremental cost&#x02010;effectiveness ratio</p></def></def-item><def-item><term>IRCT</term><def><p>irreparable rotator cuff tear</p></def></def-item><def-item><term>LTTT</term><def><p>lower trapezius tendon transfer</p></def></def-item><def-item><term>NMB</term><def><p>net monetary benefit</p></def></def-item><def-item><term>PSA</term><def><p>probabilistic sensitivity analysis</p></def></def-item><def-item><term>QALYs</term><def><p>quality&#x02010;adjusted life years</p></def></def-item><def-item><term>QOL</term><def><p>quality of life</p></def></def-item><def-item><term>RSA</term><def><p>reverse shoulder arthroplasty</p></def></def-item><def-item><term>SABS</term><def><p>subacromial balloon spacer</p></def></def-item><def-item><term>SCR</term><def><p>superior capsular reconstruction</p></def></def-item><def-item><term>WTP</term><def><p>willingness&#x02010;to&#x02010;pay</p></def></def-item></def-list><sec id="jeo270180-sec-0060"><title>INTRODUCTION</title><p>The management of irreparable rotator cuff tears (IRCTs) continues to be surrounded by substantial controversy, with no clear consensus regarding their optimal treatment strategy [<xref rid="jeo270180-bib-0009" ref-type="bibr">9</xref>, <xref rid="jeo270180-bib-0011" ref-type="bibr">11</xref>, <xref rid="jeo270180-bib-0027" ref-type="bibr">27</xref>]. Management of these tears have been further complicated in recent years by an aging population with associated sarcopenia and inferior tissue quality but with increasing activity levels and shoulder functional demands [<xref rid="jeo270180-bib-0011" ref-type="bibr">11</xref>]. Thus, while reverse shoulder arthroplasty (RSA) had traditionally been considered the gold&#x02010;standard treatment strategy for IRCTs, particularly for older adults, a number of new strategies aimed at improving functional outcomes have arisen [<xref rid="jeo270180-bib-0022" ref-type="bibr">22</xref>].</p><p>Superior capsular reconstruction (SCR), lower trapezius tendon transfer (LTTT), subacromial balloon spacer implantation (SABS), and RSA currently represent four of the most common surgical options for management of IRCTs [<xref rid="jeo270180-bib-0011" ref-type="bibr">11</xref>]. The goal of these strategies is to reduce contact between the humeral head and the acromion, thus minimizing glenohumeral joint pressures, decreasing pain, and enabling the deltoid muscle to be retrained as the predominant driver of glenohumeral range of motion [<xref rid="jeo270180-bib-0011" ref-type="bibr">11</xref>]. Certain patient&#x02010; and surgeon&#x02010;specific factors, such as the presence of rotator cuff arthropathy and surgeon comfort or expertise with a specific procedure, may limit the selection of treatment for IRCTs; however, in circumstances when such factors do not preclude any one treatment, the existence of several different approaches can present a substantial challenge during shared decision&#x02010;making discussions regarding the optimal treatment strategy.</p><p>While a substantial number of studies investigating the relative efficacy of these procedures has accumulated in recent years, no study to date has directly compared the cost&#x02010;effectiveness of these procedures. Thus, while patient&#x02010; and surgeon&#x02010;specific factors often serve as primary determinants of treatment decisions and may play an important role in determining long&#x02010;term costs and outcomes associated with a variety of management options for IRCTs, understanding the relative cost associated with each procedure when several of the aforementioned treatments may be clinically appropriate may aid in decision&#x02010;making. Furthermore, given the increasing emphasis placed on value&#x02010;based care worldwide, decision&#x02010;making at the policy level will increasingly entail consideration of an intervention's demonstrated value, rather than outcomes alone.</p><p>Thus, the purpose of this study was to compare the cost&#x02010;effectiveness of SCR, LTTT, SABS, and RSA to determine the preferred cost&#x02010;effective treatment strategy for IRCTs. The authors hypothesized that RSA would prove to be the most cost&#x02010;effective treatment option for patients presenting with massive IRCTs.</p></sec><sec sec-type="methods" id="jeo270180-sec-0070"><title>METHODS</title><sec id="jeo270180-sec-0080"><title>Markov modelling process</title><p>Markov models are decision trees used to model clinical courses of treatment as transitions between discrete health states based on probabilistic events occurring over a specified period of time [<xref rid="jeo270180-bib-0002" ref-type="bibr">2</xref>]. As summarized below, each state is associated with a quality&#x02010;of&#x02010;life (QOL) value, transition probabilities, and costs that are determined from empirically&#x02010;derived or estimated data. QOL values range from 0 (death) to 1 (perfect health) and provide a measure of disease burden on an individual's life. According to the transition probabilities, experimental patients transition between health states through Markov cycles, accruing QOL values and costs at each state.</p><p>QOL values are also aggregated into quality&#x02010;adjusted life&#x02010;years (QALYs). The primary outcome of a Markov study is the incremental cost&#x02010;effectiveness ratio (ICER), which is defined as the difference in costs between two treatment options divided by the difference in QALYs for those treatments [<xref rid="jeo270180-bib-0017" ref-type="bibr">17</xref>]. For the present study, treatment strategies were (1) SCR, (2) LTTT, 3) SABS, and 4) RSA. A willingness&#x02010;to&#x02010;pay (WTP) threshold is set and defined as the maximum amount that society is willing to pay to achieve one additional QALY. A WTP of $50,000 is considered standard [<xref rid="jeo270180-bib-0025" ref-type="bibr">25</xref>]. This threshold has been widely accepted and applied across a range of similar economic analyses in orthopaedics [<xref rid="jeo270180-bib-0023" ref-type="bibr">23</xref>, <xref rid="jeo270180-bib-0026" ref-type="bibr">26</xref>, <xref rid="jeo270180-bib-0030" ref-type="bibr">30</xref>, <xref rid="jeo270180-bib-0031" ref-type="bibr">31</xref>]. If a treatment results in an ICER below the WTP threshold, it is considered cost&#x02010;effective; as a result, the treatment with the most QALYs (lowest ICER) would be considered the optimal strategy. If a treatment results in both lower costs and more QALYs, it is considered to be a &#x02018;dominant treatment&#x02019; [<xref rid="jeo270180-bib-0006" ref-type="bibr">6</xref>].</p></sec><sec id="jeo270180-sec-0090"><title>Model structure</title><p>The Markov decision tree model utilized in the current study was constructed from publicly available software (TreeAge Pro; TreeAge Software). A patient presenting with a torn and irreparable supraspinatus tendon (with or without a torn and irreparable infraspinatus tendon) as well as a torn and reparable subscapularis tendon that has failed to respond to 6 months of nonoperative therapy serves as the base case for our model. This patient represents the demographic most likely to be faced with the decision between SCR, LTTT, SABS, and RSA and most closely reflects the cohort of patients included in studies from which model inputs were derived. All patients in the model are assumed to have a symptomatic massive IRCT with no glenohumeral arthropathy, infections, allergies to polylactide or polycaprolactone, or axillary nerve palsy at the time of presentation. Following each index surgical procedure, patients follow the postoperative pathway as depicted in Figure&#x000a0;<xref rid="jeo270180-fig-0001" ref-type="fig">1</xref>. Probabilistic subsets of patients experiencing a surgical complication after SCR, LTTT, or SABS are assumed to undergo either conversion to RSA or arthroscopic revision based on probabilities derived from the literature, while patients who experience a surgical complication after RSA are assumed to undergo revision RSA.</p><fig position="float" fig-type="Figure" id="jeo270180-fig-0001"><label>Figure 1</label><caption><p>Markov model diagram depicting flow of patients in the decision model. *Patients experiencing a surgical complication after RSA are assumed to undergo revision RSA. IRCT, irreparable rotator cuff tear; LTTT, lower trapezius tendon transfer; RSA, reverse shoulder arthroplasty; SABS, subacromial balloon spacer; SCR, superior capsular reconstruction.</p></caption><graphic xlink:href="JEO2-12-e70180-g005" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="jeo270180-sec-0100"><title>Model parameters</title><p>To obtain outcomes and model inputs for patients with IRCTs treated with SCR, LTTT, SABS, and RSA, a targeted literature search was performed. Reoperation rates including conversion to RSA as well as revision RSA after a primary RSA were derived from six recent systematic reviews evaluating outcomes after management of IRCTs with each surgical option (Table&#x000a0;<xref rid="jeo270180-tbl-0001" ref-type="table">1</xref>) [<xref rid="jeo270180-bib-0003" ref-type="bibr">3</xref>, <xref rid="jeo270180-bib-0010" ref-type="bibr">10</xref>, <xref rid="jeo270180-bib-0019" ref-type="bibr">19</xref>, <xref rid="jeo270180-bib-0020" ref-type="bibr">20</xref>, <xref rid="jeo270180-bib-0024" ref-type="bibr">24</xref>, <xref rid="jeo270180-bib-0029" ref-type="bibr">29</xref>].</p><table-wrap position="float" id="jeo270180-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Model inputs.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Base case value</th><th align="left" valign="bottom" rowspan="1" colspan="1">PSA 10%&#x02013;90% range (distribution type)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Source</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" rowspan="1">
<italic toggle="yes">Transition probabilities</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reoperation after SCR</td><td align="left" valign="top" rowspan="1" colspan="1">0.069</td><td align="left" valign="top" rowspan="1" colspan="1">0.051&#x02013;0.087 (<italic toggle="yes">&#x003b2;</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">Smith et al. [<xref rid="jeo270180-bib-0029" ref-type="bibr">29</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Conversion to RSA After SCR</td><td align="left" valign="top" rowspan="1" colspan="1">0.017</td><td align="left" valign="top" rowspan="1" colspan="1">0.013&#x02013;0.021 (<italic toggle="yes">&#x003b2;</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">Mercurio et al. [<xref rid="jeo270180-bib-0024" ref-type="bibr">24</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reoperation after LTTT</td><td align="left" valign="top" rowspan="1" colspan="1">0.075</td><td align="left" valign="top" rowspan="1" colspan="1">0.056&#x02013;0.096 (<italic toggle="yes">&#x003b2;</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">de Marinis et al. [<xref rid="jeo270180-bib-0010" ref-type="bibr">10</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Conversion to RSA After LTTT</td><td align="left" valign="top" rowspan="1" colspan="1">0.05</td><td align="left" valign="top" rowspan="1" colspan="1">0.037&#x02013;0.064 (<italic toggle="yes">&#x003b2;</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">de Marinis et al. [<xref rid="jeo270180-bib-0010" ref-type="bibr">10</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reoperation after SABS</td><td align="left" valign="top" rowspan="1" colspan="1">0.069</td><td align="left" valign="top" rowspan="1" colspan="1">0.051&#x02013;0.088 (<italic toggle="yes">&#x003b2;</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">Levy et al. [<xref rid="jeo270180-bib-0020" ref-type="bibr">20</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Conversion to RSA after SABS</td><td align="left" valign="top" rowspan="1" colspan="1">0.05</td><td align="left" valign="top" rowspan="1" colspan="1">0.037&#x02013;0.063 (<italic toggle="yes">&#x003b2;</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">Berk et al. [<xref rid="jeo270180-bib-0003" ref-type="bibr">3</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Revision RSA</td><td align="left" valign="top" rowspan="1" colspan="1">0.08</td><td align="left" valign="top" rowspan="1" colspan="1">0.061&#x02013;0.099 (<italic toggle="yes">&#x003b2;</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">Kovacevic et al. [<xref rid="jeo270180-bib-0019" ref-type="bibr">19</xref>]</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<italic toggle="yes">Costs (US $)</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SCR</td><td align="left" valign="top" rowspan="1" colspan="1">$20,837</td><td align="left" valign="top" rowspan="1" colspan="1">$15,546&#x02013;$26,343 (<italic toggle="yes">&#x003b3;</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">Marigi et al. [<xref rid="jeo270180-bib-0022" ref-type="bibr">22</xref>], Institutional Data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LTTT</td><td align="left" valign="top" rowspan="1" colspan="1">$16,915</td><td align="left" valign="top" rowspan="1" colspan="1">$12,754&#x02013;$21,581 (<italic toggle="yes">&#x003b3;</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">Marigi et al. [<xref rid="jeo270180-bib-0022" ref-type="bibr">22</xref>], Institutional Data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SABS</td><td align="left" valign="top" rowspan="1" colspan="1">$9,058</td><td align="left" valign="top" rowspan="1" colspan="1">$6,894&#x02013;$11,487 (<italic toggle="yes">&#x003b3;</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">Luthringer et al. [<xref rid="jeo270180-bib-0021" ref-type="bibr">21</xref>], Institutional Data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RSA</td><td align="left" valign="top" rowspan="1" colspan="1">$17,210</td><td align="left" valign="top" rowspan="1" colspan="1">$12,996&#x02013;$22,041 (<italic toggle="yes">&#x003b3;</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">Marigi et al. [<xref rid="jeo270180-bib-0022" ref-type="bibr">22</xref>], Institutional Data</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<italic toggle="yes">Utilities</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Success after SCR</td><td align="left" valign="top" rowspan="1" colspan="1">0.76</td><td align="left" valign="top" rowspan="1" colspan="1">0.69&#x02013;0.82 (normal)</td><td align="left" valign="top" rowspan="1" colspan="1">Mercurio et al. [<xref rid="jeo270180-bib-0024" ref-type="bibr">24</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Success after LTTT</td><td align="left" valign="top" rowspan="1" colspan="1">0.67</td><td align="left" valign="top" rowspan="1" colspan="1">0.61&#x02013;0.74 (normal)</td><td align="left" valign="top" rowspan="1" colspan="1">de Marinis et al. [<xref rid="jeo270180-bib-0010" ref-type="bibr">10</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Success after SABS</td><td align="left" valign="top" rowspan="1" colspan="1">0.69</td><td align="left" valign="top" rowspan="1" colspan="1">0.62&#x02013;0.75 (normal)</td><td align="left" valign="top" rowspan="1" colspan="1">Berk et al. [<xref rid="jeo270180-bib-0003" ref-type="bibr">3</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Success after RSA</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td><td align="left" valign="top" rowspan="1" colspan="1">0.52&#x02013;0.65 (normal)</td><td align="left" valign="top" rowspan="1" colspan="1">Kovacevic et al. [<xref rid="jeo270180-bib-0019" ref-type="bibr">19</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Failure</td><td align="left" valign="top" rowspan="1" colspan="1">0.35</td><td align="left" valign="top" rowspan="1" colspan="1">0.28&#x02013;0.42 (normal)</td><td align="left" valign="top" rowspan="1" colspan="1">Berk et al. [<xref rid="jeo270180-bib-0003" ref-type="bibr">3</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="jeo270180-tbl1-note-0001"><p>Abbreviations: LTTT, lower trapezius tendon transfer; RSA, reverse shoulder arthroplasty; SABS, subacromial balloon spacer; SCR, superior capsular reconstruction.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Costs were considered from the payer perspective (commercial or government). Costs for each treatment strategy and transition state in the model were derived from the published literature and verified against actual patients&#x02019; costs at our institution (a large, academic medical centre) for accuracy and reliability (Table&#x000a0;<xref rid="jeo270180-tbl-0001" ref-type="table">1</xref>) [<xref rid="jeo270180-bib-0021" ref-type="bibr">21</xref>, <xref rid="jeo270180-bib-0022" ref-type="bibr">22</xref>]. The cost for arthroscopic revisions were assumed to be 5% greater than their primary counterparts based on prior cost&#x02010;effectiveness analyses [<xref rid="jeo270180-bib-0013" ref-type="bibr">13</xref>, <xref rid="jeo270180-bib-0018" ref-type="bibr">18</xref>].</p><p>The Constant&#x02010;Murley score (CMS) was used to quantify the utility of each treatment strategy based on the outcomes of four recent systematic reviews on SCR, LTTT, SABS, and RSA performed in patients with IRCTs (Table&#x000a0;<xref rid="jeo270180-tbl-0001" ref-type="table">1</xref>) [<xref rid="jeo270180-bib-0003" ref-type="bibr">3</xref>, <xref rid="jeo270180-bib-0010" ref-type="bibr">10</xref>, <xref rid="jeo270180-bib-0019" ref-type="bibr">19</xref>, <xref rid="jeo270180-bib-0024" ref-type="bibr">24</xref>]. The CMS was selected, as it was the most commonly reported patient&#x02010;reported outcome measure among each of the four treatment strategies and provides an overall measure of shoulder function that can be used to approximate shoulder&#x02010;related quality of life [<xref rid="jeo270180-bib-0001" ref-type="bibr">1</xref>]. To convert from the CMS 100&#x02010;point scale to the shoulder&#x02010;related QOL values used as model inputs, scores were scaled by a factor of 1/100 such that they ranged between 0 and 1.</p></sec><sec id="jeo270180-sec-0110"><title>Monte Carlo microsimulation and probabilistic sensitivity analysis (PSA)</title><p>In contrast to methods used to create predictive models with fixed input values, Monte Carlo simulation enables the construction of models that leverage probability distributions for variables with inherent uncertainty. In the present study, Monte Carlo microsimulation was used to generate hypothetical patients who repeatedly traverse the model, each time with a set of different input parameters drawn from a corresponding probability distribution. For each microsimulation, patients accrue costs and utilities, and these are averaged and compared over many simulated cycles to produce more robust results that consider the uncertainty associated with estimated model inputs. A greater number of cycles that produce similar results corresponds to increased confidence that the result in question does in fact reflect reality despite the inherent uncertainty associated with selected input parameters.</p><p>In this study, PSA was used to simultaneously vary all cost, utility, and transition probability input parameters in the model. PSA has been shown to better estimate uncertainty in the model when compared to standard sensitivity analysis for microsimulation models [<xref rid="jeo270180-bib-0004" ref-type="bibr">4</xref>, <xref rid="jeo270180-bib-0014" ref-type="bibr">14</xref>]. One thousand patients were simulated over 1,000 cycles, with (1) cost parameters assigned gamma distributions based on their means, (2) probability parameters assigned beta distributions based on their means, and (3) utilities assigned normal distributions based on their means [<xref rid="jeo270180-bib-0012" ref-type="bibr">12</xref>]. Standard deviations for probabilities and costs were assumed to be 20% of the mean based on prior analyses [<xref rid="jeo270180-bib-0007" ref-type="bibr">7</xref>]. For utility values, a standard deviation of 0.05 was assumed. In this study, both costs and QALYs were discounted at a rate of 3% annually [<xref rid="jeo270180-bib-0028" ref-type="bibr">28</xref>]. The ICER was used to evaluate the cost&#x02010;effectiveness of each treatment arm by providing a measure of the cost per year acquired by undergoing the specific treatment arm that results in the highest number of QALYs. Cycle length was defined as one year, with an overall time&#x02010;horizon of 10 years.</p></sec></sec><sec sec-type="results" id="jeo270180-sec-0120"><title>RESULTS</title><sec id="jeo270180-sec-0130"><title>Monte Carlo microsimulation and PSA</title><p>The results of the Monte Carlo microsimulation and PSA are shown in Table&#x000a0;<xref rid="jeo270180-tbl-0002" ref-type="table">2</xref>. Mean total costs of SCR, RSA, LTTT, and SABS were $30,540&#x02009;&#x000b1;&#x02009;5,770, $26,896&#x02009;&#x000b1;&#x02009;5,622, $25,819&#x02009;&#x000b1;&#x02009;4,325, and $16,412&#x02009;&#x000b1;&#x02009;2,583, respectively. On average, total QALYs from SCR, RSA, LTTT, and SABS were 6.17&#x02009;&#x000b1;&#x02009;0.53, 3.78&#x02009;&#x000b1;&#x02009;0.38, 5.33&#x02009;&#x000b1;&#x02009;0.49, and 5.59&#x02009;&#x000b1;&#x02009;0.48. Because SABS demonstrated both lower costs and greater or similar utility to LTTT and RSA, both LTTT and RSA were considered &#x02018;absolute dominated&#x02019; treatment strategies. However, because SCR demonstrated greater utility than SABS, it was considered an &#x02018;undominated&#x02019; treatment strategy despite its increased cost relative to SABS. In this case, when no treatment results in both lower costs and greater utility, the ICER is used to determine the most cost&#x02010;effective intervention at a given WTP threshold.</p><table-wrap position="float" id="jeo270180-tbl-0002" content-type="Table"><label>Table 2</label><caption><p>Results of Monte Carlo microsimulation and PSA.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="&#x000b1;" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="&#x000b1;" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="&#x000b1;" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="." style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Dominance</th><th align="left" valign="bottom" rowspan="1" colspan="1">Strategy</th><th align="left" valign="bottom" rowspan="1" colspan="1">Cost ($)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Incremental cost ($)<xref rid="jeo270180-tbl2-note-0002" ref-type="table-fn">a</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Effectiveness (QALYs)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Incremental effectiveness (QALYs)<xref rid="jeo270180-tbl2-note-0002" ref-type="table-fn">a</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">ICER ($/QALY)</th><th align="left" valign="bottom" rowspan="1" colspan="1">NMB ($)<xref rid="jeo270180-tbl2-note-0003" ref-type="table-fn">b</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">% Iterations cost&#x02010;effective (%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Undominated</td><td align="left" valign="top" rowspan="1" colspan="1">SABS</td><td align="char" valign="top" rowspan="1" colspan="1">16,412&#x02009;&#x000b1;&#x02009;2583</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">5.59&#x02009;&#x000b1;&#x02009;0.48</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">263,082&#x02009;&#x000b1;&#x02009;24,628</td><td align="char" valign="top" rowspan="1" colspan="1">31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Absolute dominated</td><td align="left" valign="top" rowspan="1" colspan="1">LTTT</td><td align="char" valign="top" rowspan="1" colspan="1">25,819&#x02009;&#x000b1;&#x02009;4325</td><td align="left" valign="top" rowspan="1" colspan="1">+9406</td><td align="char" valign="top" rowspan="1" colspan="1">5.33&#x02009;&#x000b1;&#x02009;0.49</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.26</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;36,247.55</td><td align="char" valign="top" rowspan="1" colspan="1">240,701&#x02009;&#x000b1;&#x02009;25,784</td><td align="char" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Absolute dominated</td><td align="left" valign="top" rowspan="1" colspan="1">RSA</td><td align="char" valign="top" rowspan="1" colspan="1">26,896&#x02009;&#x000b1;&#x02009;5622</td><td align="left" valign="top" rowspan="1" colspan="1">+10,483</td><td align="char" valign="top" rowspan="1" colspan="1">3.78&#x02009;&#x000b1;&#x02009;0.38</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.81</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;5782.28</td><td align="char" valign="top" rowspan="1" colspan="1">161,947&#x02009;&#x000b1;&#x02009;20,912</td><td align="char" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Undominated</td><td align="left" valign="top" rowspan="1" colspan="1">SCR</td><td align="char" valign="top" rowspan="1" colspan="1">30,540&#x02009;&#x000b1;&#x02009;5770</td><td align="left" valign="top" rowspan="1" colspan="1">+14,127</td><td align="char" valign="top" rowspan="1" colspan="1">6.17&#x02009;&#x000b1;&#x02009;0.53</td><td align="left" valign="top" rowspan="1" colspan="1">+0.58</td><td align="left" valign="top" rowspan="1" colspan="1">24,332.09</td><td align="char" valign="top" rowspan="1" colspan="1">277,985&#x02009;&#x000b1;&#x02009;27,986</td><td align="char" valign="top" rowspan="1" colspan="1">60</td></tr></tbody></table><table-wrap-foot><fn id="jeo270180-tbl2-note-0001"><p>Abbreviations: ICER, incremental cost&#x02010;effectiveness ratio; LTTT, lower trapezius tendon transfer; NMB, net monetary benefit; PSA, probabilistic sensitivity analysis; QALY, quality adjusted life year; RSA, reverse shoulder arthroplasty; SABS, subacromial balloon spacer; SCR, superior capsular reconstruction.</p></fn><fn id="jeo270180-tbl2-note-0002"><label>a</label><p>Relative to SABS.</p></fn><fn id="jeo270180-tbl2-note-0003"><label>b</label><p>The NMB represents the value of an intervention in monetary terms when a willingness to pay threshold for a unit of benefit (one QALY) is known. It is calculated as the benefit of a therapy expressed in monetary terms minus the costs associated with that therapy.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Assuming the standard $50,000 WTP threshold for cost&#x02010;effective interventions [<xref rid="jeo270180-bib-0025" ref-type="bibr">25</xref>], SCR was determined to be the most cost&#x02010;effective treatment strategy, with an ICER of $24,332/QALY relative to SABS. Figure&#x000a0;<xref rid="jeo270180-fig-0002" ref-type="fig">2</xref> displays cost&#x02010;effectiveness acceptability curves for each treatment strategy at WTP thresholds from $0/QALY to $50,000/QALY. The WTP threshold below which SABS became cost&#x02010;effective over SCR was found to be less than $25,000/QALY, suggesting that SCR is a highly cost&#x02010;effective treatment strategy, even at lower WTP thresholds.</p><fig position="float" fig-type="Figure" id="jeo270180-fig-0002"><label>Figure 2</label><caption><p>Cost&#x02010;effectiveness (CE) acceptability curves for each treatment strategy at willingness&#x02010;to&#x02010;pay thresholds from $0/QALY to $50,000/QALY. SCR, superior capsular reconstruction; LTTT, lower trapezius tendon transfer; QALY, quality adjusted life year; RSA, reverse shoulder arthroplasty; SABS, subacromial balloon spacer.</p></caption><graphic xlink:href="JEO2-12-e70180-g004" position="anchor" id="jats-graphic-3"/></fig><p>Figure&#x000a0;<xref rid="jeo270180-fig-0003" ref-type="fig">3</xref> shows the net monetary benefit (NMB) of each treatment strategy at WTP thresholds from $0/QALY to $100,000/QALY. The NMB represents the value of an intervention in monetary terms when a WTP threshold for a unit of benefit (one QALY) is known. It is calculated as the benefit of a therapy expressed in monetary terms minus the costs associated with that therapy.</p><fig position="float" fig-type="Figure" id="jeo270180-fig-0003"><label>Figure 3</label><caption><p>Net monetary benefit (NMB) of each treatment strategy at willingness&#x02010;to&#x02010;pay thresholds from $0/QALY to $100,000/QALY. LTTT, lower trapezius tendon transfer; QALY, quality adjusted life year; RSA, reverse shoulder arthroplasty; SABS, subacromial balloon spacer; SCR, superior capsular reconstruction.</p></caption><graphic xlink:href="JEO2-12-e70180-g003" position="anchor" id="jats-graphic-5"/></fig><p>Results of the microsimulation and PSA are depicted in Figure&#x000a0;<xref rid="jeo270180-fig-0004" ref-type="fig">4</xref>. Out of 1000 samples run over 1000 trials, SCR was determined the preferred, most cost&#x02010;effective strategy for 60% of patients included in the microsimulation model, with SABS being the optimal strategy in 31% of cases, and LTTT the optimal strategy in the remaining 9% of cases.</p><fig position="float" fig-type="Figure" id="jeo270180-fig-0004"><label>Figure 4</label><caption><p>Costs and quality adjusted life years (quality adjusted life years [QALYs]) gained per patient for each of the 1000 patients in the Monte Carlo microsimulation model. LTTT, lower trapezius tendon transfer; RSA, reverse shoulder arthroplasty; SABS, subacromial balloon spacer; SCR, superior capsular reconstruction.</p></caption><graphic xlink:href="JEO2-12-e70180-g002" position="anchor" id="jats-graphic-7"/></fig><p>The ICER scatterplots shown in Figure&#x000a0;<xref rid="jeo270180-fig-0005" ref-type="fig">5</xref> illustrate the model's predictions and confidence for patients faced with the decision of SCR versus LTTT, SCR versus SABS, and SABS versus LTTT. Points in green correspond to patients for whom the model correctly predicted the most cost&#x02010;effective treatment strategy (SCR over LTTT, SCR over SABS, or SABS over LTTT), while points in red correspond to patients for whom the alternative strategy would have been the most cost&#x02010;effective treatment strategy. The model's confidence is shown with a 95% confidence ellipse.</p><fig position="float" fig-type="Figure" id="jeo270180-fig-0005"><label>Figure 5</label><caption><p>Incremental cost&#x02010;effectiveness scatterplots from the probabilistic sensitivity analysis (PSA), shown with 95% confidence ellipses. All points to the right of the diagonal willingness&#x02010;to&#x02010;pay (WTP) line represent patients for whom the model predicted superior capsular reconstruction (SCR) (a and b) or subacromial balloon spacer (SABS) (c) as more cost&#x02010;effective than lower trapezius tendon transfer (LTTT) (a and b) or SABS (b) at a WTP of $50,000/quality adjusted life years (QALYs) (green). Points to the left of the $50,000 WTP diagonal correspond to patients for whom LTTT (a and c) or SABS (b) is the optimal strategy (red), and points both below the $0 incremental cost line and to the right of the $50,000 WTP line correspond to patients for whom the points in green represent the dominant preferred treatment strategy.</p></caption><graphic xlink:href="JEO2-12-e70180-g001" position="anchor" id="jats-graphic-9"/></fig></sec></sec><sec sec-type="discussion" id="jeo270180-sec-0140"><title>DISCUSSION</title><p>The primary findings of the current study were (1) SCR was determined to be the most cost&#x02010;effective treatment strategy for the management of IRCTs when compared to SABS, LTTT, and RSA, (2) SABS may be a cost&#x02010;effective alternative treatment option for the management of IRCTs when compared to LTTT and at low WTP thresholds, and (3) LTTT and RSA were found to be &#x02018;absolute dominated&#x02019; treatment strategies, resulting in neither greater utility nor lower costs when compared to SABS.</p><p>As these results were determined across a range of procedural costs, they can be more broadly and confidently applied to different practice types and locations. A recent scoping review found extremely limited data published on the cost of SCR, with only two studies meeting the authors&#x02019; inclusion criteria [<xref rid="jeo270180-bib-0015" ref-type="bibr">15</xref>]. They concluded that primary drivers of cost associated with SCR were related to intraoperative factors including implants, specifically human dermal allograft and anchors, as well as operative time. The authors argued that future studies not only reporting costs, but also the cost&#x02010;effectiveness of the procedure, were necessary to quantify whether the high costs of SCR can be justified by an associated improved utility [<xref rid="jeo270180-bib-0015" ref-type="bibr">15</xref>]. Only a single&#x02010;institution analysis comparing SCR to RSA at short&#x02010;term follow&#x02010;up has reported some form of a related metric that attempted incorporate both costs and outcomes, which was defined as the change in the American Shoulder and Elbow Surgeons (ASES) score divided by total direct costs per $10,000 [<xref rid="jeo270180-bib-0016" ref-type="bibr">16</xref>]. The authors were unable to demonstrate a statistically significant difference in value between RSA and SCR using this metric [<xref rid="jeo270180-bib-0016" ref-type="bibr">16</xref>]. This could be explained by the single&#x02010;institution nature of the study, relatively small sample size with only 30 RSAs and 126 SCRs included for analysis, short&#x02010;term follow&#x02010;up of just one&#x02010;year, and the potential learning curve associated with SCR as a relatively new procedure [<xref rid="jeo270180-bib-0016" ref-type="bibr">16</xref>]. The authors did report significant differences in both operating room time and complication rates between the two procedures, with SCR demonstrating a significantly longer operating room time (204 vs. 108&#x02009;min) and significantly lower complication rate (3% vs. 13%) compared to RSA [<xref rid="jeo270180-bib-0016" ref-type="bibr">16</xref>]. These findings would align with the results of our model demonstrating both greater costs (theoretically associated with longer operating room time) but also the greatest number of QALYs achieved (potential for fewer complications) with SCR, as operating room time has been shown to be one of the greatest contributors to the cost of SCR [<xref rid="jeo270180-bib-0015" ref-type="bibr">15</xref>, <xref rid="jeo270180-bib-0022" ref-type="bibr">22</xref>].</p><p>The current study demonstrated that SABS may be a cost&#x02010;effective treatment strategy for IRCTs when performed in appropriately selected patients, with average costs totalling $16,412&#x02009;&#x000b1;&#x02009;2583 and average QALYs totalling 5.59&#x02009;&#x000b1;&#x02009;0.48. Importantly, while QALYs achieved with SABS were comparable to those of the other procedures, total costs were substantially lower. This finding aligns with two prior cost analyses of SABS that demonstrated substantially lower upfront costs with SABS relative to the other procedures included in this study: one study compared SABS to partial rotator cuff repair, RSA, and conservative management in the Italian healthcare system [<xref rid="jeo270180-bib-0005" ref-type="bibr">5</xref>], while one compared SABS to partial rotator cuff repair in the United States [<xref rid="jeo270180-bib-0021" ref-type="bibr">21</xref>]. This cost was validated against our own institutional cost data, which also confirmed substantially lower upfront costs with SABS relative to SCR, LTTT, and RSA. Because of these reduced upfront costs, likely due to reduced operating room time, SABS was able to produce moderate outcomes relative to the other procedures and remain cost&#x02010;effective. It is important to note, however, that prior work has shown SABS to be most beneficial for a relatively specific patient population with IRCTs, and thus the indications for SABS may be slightly different than those for SCR, LTTT, or RSA [<xref rid="jeo270180-bib-0008" ref-type="bibr">8</xref>]. Indeed, ideal candidates for SABS are patients with IRCTs and an intact subscapularis with a chief complaint of pain, but who also present with a preserved range of motion [<xref rid="jeo270180-bib-0008" ref-type="bibr">8</xref>]. Therefore, SABS may be beneficial in patients with medical comorbidities that would otherwise limit the use of other techniques dependent on biologic tissue healing (i.e., SCR, LTTT) or whose medical profile was such that the amount of time exposed to anaesthesia needs to be limited. However, poor candidates for SABS would include patients with pseudoparalysis, axillary nerve palsy, irreparable subscapularis tears, or severe glenohumeral arthritis (Hamada grade&#x02009;&#x02265;&#x02009;3); [<xref rid="jeo270180-bib-0008" ref-type="bibr">8</xref>] for these patients, SABS would likely prove not cost&#x02010;effective and other treatments included in this study should be considered.</p><p>Neither LTTT nor RSA demonstrated superior cost&#x02010;effectiveness when compared to the alternative treatment strategies considered in the model. These findings are likely explained by lower functional scores relative to SCR and increased costs relative to SABS. For example, a recent systematic review comparing patient&#x02010;reported outcomes after different treatment strategies for IRCTs found that patients who received RSA demonstrated an average CMS score of just 59 [<xref rid="jeo270180-bib-0019" ref-type="bibr">19</xref>]. In comparison, the average CMS score for patients undergoing SCR was 76 [<xref rid="jeo270180-bib-0024" ref-type="bibr">24</xref>]. This greater functionality translates to greater utility and provides one explanation for why SCR and LTTT were found to be more cost&#x02010;effective than RSA. However, it is again important to consider individual patient factors when deciding between RSA and other surgical treatment alternatives for IRCTs, as a number of patient&#x02010;specific factors and comorbidities that limit tissue healing may predispose some patients to experience greater cost&#x02010;utility with RSA relative to the other procedures included in the present model. In addition, it is important to note that all patients in the current model were assumed to have a symptomatic massive IRCT with <italic toggle="yes">no</italic> glenohumeral arthropathy. This likely biased the model to favour all treatments except RSA. If a different patient demographic, such as one <italic toggle="yes">with</italic> glenohumeral arthropathy, had been selected to serve as the base case for our model, outcomes would have likely differed. For example, in scenarios involving patients with glenohumeral arthropathy, it is likely that RSA would be determined to be one of the cost&#x02010;effective treatment options.</p><sec id="jeo270180-sec-0150"><title>Limitations</title><p>There are limitations to this study that should be noted to ensure interpretation of the results in their proper context. First, a Markov model is a rigid model for an &#x02018;average&#x02019; patient undergoing a treatment and must define definitive likelihoods of treatment failure, costs, and treatment pathways. While this limitation is minimized when applying Monte Carlo microsimulation and PSA, our methodology did not capture the unique experience of every patient undergoing treatment for an IRCT. In practice, numerous factors that could not be captured in this model exist and may influence decision making. Second, to conduct the analysis, assumptions regarding transition probabilities and outcomes using the current literature were necessary. Finally, as multiple factors contribute to an individual patient's potential for tissue healing, implant integration, and quality of life, the current results may not be generalizable to all patients. This limitation is mitigated by performing sensitivity analyses that account for a spectrum of model inputs; however, it is not possible to remove all uncertainty from the analysis.</p></sec></sec><sec sec-type="conclusions" id="jeo270180-sec-0160"><title>CONCLUSION</title><p>SCR was found to be the most cost&#x02010;effective treatment option for IRCTs based on the current microsimulation and probabilistic sensitivity analyses, although LTTT and SABS were also found to be cost&#x02010;effective in select patients. Given that this statistical model does not consider the unique experiences of individual patients, shared decision&#x02010;making remains an important component in determining the optimal treatment strategy for IRCTs.</p></sec><sec id="jeo270180-sec-0170"><title>AUTHOR CONTRIBUTIONS</title><p>
<italic toggle="yes">Conceptualization, data procurement and analysis, writing of initial manuscript, manuscript revision</italic>: Jacob Oeding. <italic toggle="yes">Manuscript revision</italic>: Kyle Kunze, Ayoosh Pareek, Kristian Samuelsson.</p></sec><sec sec-type="COI-statement" id="jeo270180-sec-0180"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no conflicts of interest.</p></sec><sec id="jeo270180-sec-0210"><title>ETHICS STATEMENT</title><p>This study was exempt from institutional review board approval.</p></sec></body><back><sec sec-type="data-availability" id="jeo270180-sec-0200"><title>DATA AVAILABILITY STATEMENT</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="jeo270180-bibl-0001"><title>REFERENCES</title><ref id="jeo270180-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jeo270180-cit-0001">
<string-name>
<surname>Ashton</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Savage&#x02010;Elliott</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Granruth</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>What are we measuring? A systematic review of outcome measurements used in shoulder surgery</article-title>. <source>Arthrosc Sports Med Rehabil</source>. <year>2020</year>;<volume>2</volume>:<fpage>e429</fpage>&#x02013;<lpage>e434</lpage>.<pub-id pub-id-type="pmid">32875307</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jeo270180-cit-0002">
<string-name>
<surname>Beck</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Pauker</surname>
<given-names>SG</given-names>
</string-name>. <article-title>The Markov process in medical prognosis</article-title>. <source>Med Decis Making</source>. <year>1983</year>;<volume>3</volume>:<fpage>419</fpage>&#x02013;<lpage>458</lpage>.<pub-id pub-id-type="pmid">6668990</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jeo270180-cit-0003">
<string-name>
<surname>Berk</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Cregar</surname>
<given-names>WM</given-names>
</string-name>, <string-name>
<surname>Gachigi</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Trofa</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Schiffern</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Hamid</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Outcomes of subacromial balloon spacer implantation for irreparable rotator cuff tears: a systematic review and meta&#x02010;analysis</article-title>. <source>J Shoulder Elbow Surg</source>. <year>2023</year>;<volume>32</volume>:<fpage>2180</fpage>&#x02013;<lpage>2191</lpage>.<pub-id pub-id-type="pmid">37247776</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jeo270180-cit-0004">
<string-name>
<surname>Briggs</surname>
<given-names>AH</given-names>
</string-name>. <article-title>Statistical approaches to handling uncertainty in health economic evaluation</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2004</year>;<volume>16</volume>:<fpage>551</fpage>&#x02013;<lpage>561</lpage>.<pub-id pub-id-type="pmid">15167156</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jeo270180-cit-0005">
<string-name>
<surname>Castagna</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Garofalo</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Maman</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gray</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Brooks</surname>
<given-names>EA</given-names>
</string-name>. <article-title>Comparative cost&#x02010;effectiveness analysis of the subacromial spacer for irreparable and massive rotator cuff tears</article-title>. <source>Int Orthop</source>. <year>2019</year>;<volume>43</volume>:<fpage>395</fpage>&#x02013;<lpage>403</lpage>.<pub-id pub-id-type="pmid">30066101</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jeo270180-cit-0006">
<string-name>
<surname>Cohen</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Reynolds</surname>
<given-names>MR</given-names>
</string-name>. <article-title>Interpreting the results of cost&#x02010;effectiveness studies</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>52</volume>:<fpage>2119</fpage>&#x02013;<lpage>2126</lpage>.<pub-id pub-id-type="pmid">19095128</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jeo270180-cit-0007">
<string-name>
<surname>Crall</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Bishop</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Guttman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kocher</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bozic</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lubowitz</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Cost&#x02010;effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first&#x02010;time anterior glenohumeral dislocations</article-title>. <source>Arthroscopy</source>. <year>2012</year>;<volume>28</volume>:<fpage>1755</fpage>&#x02013;<lpage>1765</lpage>.<pub-id pub-id-type="pmid">23040837</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jeo270180-cit-0008">
<string-name>
<surname>Dasari</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>ZA</given-names>
</string-name>, <string-name>
<surname>Swindell</surname>
<given-names>HW</given-names>
</string-name>, <string-name>
<surname>Mehta</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kerzner</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Verma</surname>
<given-names>NN</given-names>
</string-name>. <article-title>Subacromial balloon spacer: indications, rationale, and technique</article-title>. <source>JBJS Essent Surg Tech</source>. <year>2022</year>;<volume>12</volume>:<elocation-id>e21.00069</elocation-id>.</mixed-citation></ref><ref id="jeo270180-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jeo270180-cit-0009">
<string-name>
<surname>Davies</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Reilly</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sabharwal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Malhas</surname>
<given-names>A</given-names>
</string-name>. <article-title>Superior capsule reconstruction, partial cuff repair, graft interposition, arthroscopic debridement or balloon spacers for large and massive irreparable rotator cuff tears: a systematic review and meta&#x02010;analysis</article-title>. <source>J Orthop Surg</source>. <year>2022</year>;<volume>17</volume>:<fpage>552</fpage>.</mixed-citation></ref><ref id="jeo270180-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jeo270180-cit-0010">
<string-name>
<surname>de Marinis</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Marigi</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Atwan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Velasquez Garcia</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Morrey</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Sanchez&#x02010;Sotelo</surname>
<given-names>J</given-names>
</string-name>. <article-title>Lower trapezius transfer improves clinical outcomes with a rate of complications and reoperations comparable to other surgical alternatives in patients with functionally irreparable rotator cuff tears: a systematic review</article-title>. <source>Arthroscopy</source>. <year>2024</year>;<volume>40</volume>:<fpage>950</fpage>&#x02013;<lpage>959</lpage>.<pub-id pub-id-type="pmid">37394146</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jeo270180-cit-0011">
<string-name>
<surname>Dey Hazra</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Dey Hazra</surname>
<given-names>RO</given-names>
</string-name>, <string-name>
<surname>Hanson</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Ganokroj</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Vopat</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Rutledge</surname>
<given-names>JC</given-names>
</string-name>, et al. <article-title>Treatment options for massive irreparable rotator cuff tears: a review of arthroscopic surgical options</article-title>. <source>EFORT Open Rev</source>. <year>2023</year>;<volume>8</volume>:<fpage>35</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">36705608</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jeo270180-cit-0012">
<string-name>
<surname>Dodd</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bassi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bodger</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Williamson</surname>
<given-names>P</given-names>
</string-name>. <article-title>A comparison of multivariable regression models to analyse cost data</article-title>. <source>J Eval Clin Pract</source>. <year>2006</year>;<volume>12</volume>:<fpage>76</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">16422782</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jeo270180-cit-0013">
<string-name>
<surname>Dornan</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Katthagen</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Tahal</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Petri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Greenspoon</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Denard</surname>
<given-names>PJ</given-names>
</string-name>, et al. <article-title>Cost&#x02010;effectiveness of arthroscopic rotator cuff repair versus reverse total shoulder arthroplasty for the treatment of massive rotator cuff tears in patients with pseudoparalysis and nonarthritic shoulders</article-title>. <source>Arthroscopy</source>. <year>2017</year>;<volume>33</volume>:<fpage>716</fpage>&#x02013;<lpage>725</lpage>.<pub-id pub-id-type="pmid">27939409</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jeo270180-cit-0014">
<string-name>
<surname>Doubilet</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Begg</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Weinstein</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Braun</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>McNeil</surname>
<given-names>BJ</given-names>
</string-name>. <article-title>Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach</article-title>. <source>Med Decis Making</source>. <year>1985</year>;<volume>5</volume>:<fpage>157</fpage>&#x02013;<lpage>177</lpage>.<pub-id pub-id-type="pmid">3831638</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jeo270180-cit-0015">
<string-name>
<surname>Evans</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schultz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Salisbury</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bacak</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Tihista</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fitzpatrick</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Cost of superior capsular reconstruction is understudied: a scoping review</article-title>. <source>J Orthop Bus</source>. <year>2023</year>;<volume>3</volume>:<fpage>8</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="jeo270180-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jeo270180-cit-0016">
<string-name>
<surname>Gabig</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Burkhart</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Denard</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Proffitt</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Hartzler</surname>
<given-names>RU</given-names>
</string-name>. <article-title>Similar value demonstrated in the short&#x02010;term outcomes of superior capsular reconstruction and reverse shoulder arthroplasty for massive rotator cuff tears</article-title>. <source>Arthrosc Sports Med Rehabil</source>. <year>2023</year>;<volume>5</volume>:<fpage>e249</fpage>&#x02013;<lpage>e255</lpage>.<pub-id pub-id-type="pmid">36866303</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jeo270180-cit-0017">
<string-name>
<surname>Gafni</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Birch</surname>
<given-names>S</given-names>
</string-name>. <article-title>Incremental cost&#x02010;effectiveness ratios (ICERs): the silence of the lambda</article-title>. <source>Soc Sci Med</source>. <year>2006</year>;<volume>62</volume>:<fpage>2091</fpage>&#x02013;<lpage>2100</lpage>.<pub-id pub-id-type="pmid">16325975</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jeo270180-cit-0018">
<string-name>
<surname>Genuario</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Donegan</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Hamman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bell</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Boublik</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schlegel</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>The cost&#x02010;effectiveness of single&#x02010;row compared with double&#x02010;row arthroscopic rotator cuff repair</article-title>. <source>J Bone Jt Surg</source>. <year>2012</year>;<volume>94</volume>:<fpage>1369</fpage>&#x02013;<lpage>1377</lpage>.</mixed-citation></ref><ref id="jeo270180-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jeo270180-cit-0019">
<string-name>
<surname>Kovacevic</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Suriani</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Grawe</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Yian</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Gilotra</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Hasan</surname>
<given-names>SA</given-names>
</string-name>, et al. <article-title>Management of irreparable massive rotator cuff tears: a systematic review and meta&#x02010;analysis of patient&#x02010;reported outcomes, reoperation rates, and treatment response</article-title>. <source>J Shoulder Elbow Surg</source>. <year>2020</year>;<volume>29</volume>:<fpage>2459</fpage>&#x02013;<lpage>2475</lpage>.<pub-id pub-id-type="pmid">32763381</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jeo270180-cit-0020">
<string-name>
<surname>Levy</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Pujari</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Kator</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Parsons</surname>
<given-names>BO</given-names>
</string-name>, et al. <article-title>Subacromial balloon spacer implantation is a promising alternative for patients with massive irreparable rotator cuff tears: a systematic review</article-title>. <source>Arthroscopy</source>. <year>2024</year>;<volume>40</volume>:<fpage>162</fpage>&#x02013;<lpage>173.e2</lpage>.<pub-id pub-id-type="pmid">37355186</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jeo270180-cit-0021">
<string-name>
<surname>Luthringer</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Fares</surname>
<given-names>MY</given-names>
</string-name>, <string-name>
<surname>Rondon</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Vaughan</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>AZ</given-names>
</string-name>, <string-name>
<surname>Abboud</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Subacromial balloon spacer versus partial rotator cuff repair in the treatment of massive irreparable rotator cuff tears: facility personnel allocation and procedural cost analysis</article-title>. <source>Cureus</source>. <year>2023</year>;<volume>15</volume>:<elocation-id>e41538</elocation-id>. <pub-id pub-id-type="doi">10.7759/cureus.41538</pub-id>
<pub-id pub-id-type="pmid">37554620</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jeo270180-cit-0022">
<string-name>
<surname>Marigi</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>QJ</given-names>
</string-name>, <string-name>
<surname>Dholakia</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Borah</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Sanchez&#x02010;Sotelo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sperling</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Cost comparison and complication profiles of superior capsular reconstruction, lower trapezius transfer, and reverse shoulder arthroplasty for irreparable rotator cuff tears</article-title>. <source>J Shoulder Elbow Surg</source>. <year>2022</year>;<volume>31</volume>:<fpage>847</fpage>&#x02013;<lpage>854</lpage>.<pub-id pub-id-type="pmid">34592408</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jeo270180-cit-0023">
<string-name>
<surname>Mather</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Garrett</surname>
<given-names>WE</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Hussey</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bolognesi</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Lassiter</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Cost&#x02010;effectiveness analysis of the diagnosis of meniscus tears</article-title>. <source>Am J Sports Med</source>. <year>2015</year>;<volume>43</volume>:<fpage>128</fpage>&#x02013;<lpage>137</lpage>.<pub-id pub-id-type="pmid">25451791</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jeo270180-cit-0024">
<string-name>
<surname>Mercurio</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Castricini</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Castioni</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cofano</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Familiari</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gasparini</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Better functional outcomes and a lower infection rate can be expected after superior capsular reconstruction in comparison with latissimus dorsi tendon transfer for massive, irreparable posterosuperior rotator cuff tears: a systematic review</article-title>. <source>J Shoulder Elbow Surg</source>. <year>2023</year>;<volume>32</volume>:<fpage>892</fpage>&#x02013;<lpage>906</lpage>.<pub-id pub-id-type="pmid">36528222</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jeo270180-cit-0025">
<string-name>
<surname>Neumann</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Weinstein</surname>
<given-names>MC</given-names>
</string-name>. <article-title>Updating cost&#x02010;effectiveness&#x02014;the curious resilience of the $50,000&#x02010;per&#x02010;QALY threshold</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>796</fpage>&#x02013;<lpage>797</lpage>.<pub-id pub-id-type="pmid">25162885</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jeo270180-cit-0026">
<string-name>
<surname>Oeding</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Jurgensmeier</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Boos</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Krych</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Okoroha</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Moatshe</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Early surgery for partial tears of the ulnar collateral ligament may be more cost&#x02010;effective and result in longer playing careers than nonoperative management for high&#x02010;level baseball pitchers: a decision&#x02010;analytic markov model&#x02010;based analysis</article-title>. <source>Am J Sports Med</source>. <year>2024</year>;<volume>52</volume>:<fpage>2319</fpage>&#x02013;<lpage>2330</lpage>.<pub-id pub-id-type="pmid">38899340</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jeo270180-cit-0027">
<string-name>
<surname>Oh</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Rhee</surname>
<given-names>SM</given-names>
</string-name>. <article-title>Treatment strategy for irreparable rotator cuff tears</article-title>. <source>Clin Orthop Surg</source>. <year>2018</year>;<volume>10</volume>:<fpage>119</fpage>&#x02013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">29854334</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jeo270180-cit-0028">
<string-name>
<surname>Sanders</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Neumann</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Basu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Brock</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Feeny</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Krahn</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Recommendations for conduct, methodological practices, and reporting of cost&#x02010;effectiveness analyses: second panel on cost&#x02010;effectiveness in health and medicine</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>316</volume>:<fpage>1093</fpage>&#x02013;<lpage>1103</lpage>.<pub-id pub-id-type="pmid">27623463</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jeo270180-cit-0029">
<string-name>
<surname>Smith</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Gowd</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Kunkel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kaplin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hubbard</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Coates</surname>
<given-names>KE</given-names>
</string-name>, et al. <article-title>Clinical outcomes of superior capsular reconstruction for massive, irreparable rotator cuff tears: a systematic review comparing acellular dermal allograft and autograft fascia lata</article-title>. <source>Arthrosc Sports Med Rehabil</source>. <year>2021</year>;<volume>3</volume>:<fpage>e257</fpage>&#x02013;<lpage>e268</lpage>.<pub-id pub-id-type="pmid">33615273</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jeo270180-cit-0030">
<string-name>
<surname>Varady</surname>
<given-names>NH</given-names>
</string-name>, <string-name>
<surname>Oeding</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Gausden</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Ricci</surname>
<given-names>WM</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>AF</given-names>
</string-name>. <article-title>Cemented hemiarthroplasty results in substantial cost savings over uncemented hemiarthroplasty for the treatment of femoral neck fractures in patients over 60 years old: a Markov analysis</article-title>. <source>J Arthroplasty</source>. Published online October <year>2024</year>. <pub-id pub-id-type="doi">10.1016/j.arth.2024.10.098</pub-id>
</mixed-citation></ref><ref id="jeo270180-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jeo270180-cit-0031">
<string-name>
<surname>Vermue</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tack</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gryson</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Victor</surname>
<given-names>J</given-names>
</string-name>. <article-title>Can robot&#x02010;assisted total knee arthroplasty be a cost&#x02010;effective procedure? A Markov decision analysis</article-title>. <source>Knee</source>. <year>2021</year>;<volume>29</volume>:<fpage>345</fpage>&#x02013;<lpage>352</lpage>.<pub-id pub-id-type="pmid">33684865</pub-id>
</mixed-citation></ref></ref-list></back></article>